Amgen Files Definitive Proxy Statement
Ticker: AMGN · Form: DEFA14A · Filed: Apr 15, 2026
Sentiment: neutral
Topics: proxy-statement, governance, sec-filing
TL;DR
Amgen filed its proxy statement for shareholder votes. Get ready to vote!
AI Summary
Amgen Inc. filed a Definitive Proxy Statement (DEFA14A) on April 15, 2026, related to the solicitation of proxies for its annual meeting. The filing, with SEC Accession Number 0000318154-26-000040, details materials for shareholders to vote on company matters. Amgen's corporate headquarters are located at One Amgen Center Drive, Thousand Oaks, CA 91320.
Why It Matters
This filing is crucial for shareholders as it outlines the proposals and information needed to participate in Amgen's corporate governance by voting on key company decisions.
Risk Assessment
Risk Level: low — This is a routine filing for proxy solicitation and does not inherently carry financial risk.
Key Numbers
- 0000318154-26-000040 — SEC Accession Number (Unique identifier for this filing)
Key Players & Entities
- AMGEN INC (company) — Filer
- 0000318154 (company) — CIK Number for AMGEN INC
- 2026-04-15 (date) — Filing Date
- ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 (address) — Mailing and Business Address
FAQ
What type of filing is this DEFA14A?
This DEFA14A filing is for Additional definitive proxy soliciting materials and Rule 14(a)(12) material.
When was this filing accepted by the SEC?
The filing was accepted on 2026-04-15 at 16:15:02.
What is Amgen Inc.'s CIK number?
Amgen Inc.'s CIK number is 0000318154.
Where is Amgen Inc. located?
Amgen Inc.'s business and mailing address is ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320.
What is the SIC code for Amgen Inc. and what does it represent?
The SIC code is 2836, which represents Biological Products, (No Diagnostic Substances).
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 15, 2026 regarding AMGEN INC (AMGN).